Form 4: REGENXBIO Director Kenneth T. Mills Executes Stock Option Trades
SEC Form 4 Filing
Director Kenneth T. Mills of REGENXBIO Inc. reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Kenneth T. Mills, a director of REGENXBIO Inc., executed transactions involving common stock on July 16 and 17, 2024.
- These transactions involved the exercise of stock options at a price of $3.76 and the subsequent sale of shares at an average price of $13.76 to $13.80.
- On July 16, 200 shares were acquired and disposed of, and on July 17, 2,210 shares were acquired and disposed of.
- The transactions were conducted under a Rule 10b5-1 trading plan.
- Following these transactions, Mills directly owns 408,035 shares of common stock and holds options to purchase 78,944 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions. It doesn't convey any particularly positive or negative sentiment.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives and directors to have pre-arranged trading plans to avoid accusations of trading on inside information.
Key Dates
| Date | Description |
|---|---|
| 05/19/2016 | 25% of the shares subject to the option vested |
| 05/19/2025 | Expiration date of stock options |
| 07/16/2024 | Date of stock option exercise and sale of 200 shares |
| 07/17/2024 | Date of stock option exercise and sale of 2,210 shares |
| 07/18/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.